Ebola has never been a tidy biological event in East Africa. The virus moves through health facilities, markets, burial practices, family networks, transport corridors and borderlands where people cross daily for work, trade and care. A single confirmed case in Kampala, Kasese, Gulu, Bunia or Goma can quickly become more than a local alarm, testing laboratories, health worker protection, public trust, political coordination and the speed at which science reaches frightened communities. A new Perspective published in Frontiers in Tropical Diseases argues that the region must now treat mRNA vaccine platforms not as emergency-response commodities but as permanent preparedness infrastructure, embedded in surveillance, regulation, manufacturing and community systems long before the next epidemic emerges.
The urgency is grounded in recent experience. Uganda has faced repeated Sudan virus disease outbreaks, including the large 2022 event and a shorter 2025 outbreak that the World Health Organization declared on 30 January 2025 and ended on 26 April 2025 after 14 total cases, including 12 confirmed cases, two probable cases and four deaths. Small does not mean simple: that outbreak still spanned multiple districts, exposed health workers and required the tracing, monitoring and support of numerous contacts. Meanwhile, vaccine readiness remains uneven across Ebola viruses. The rVSV-ZEBOV vaccine, whose ring vaccination in Guinea showed substantial protection against Zaire ebolavirus, represents one of the great achievements of outbreak vaccinology. But Sudan and Bundibugyo ebolaviruses, both central to regional risk, still lack licensed vaccines, and their development pipelines have been thinner, slower and more dependent on emergency improvisation.
The authors, Ugwu Okechukwu Paul-Chima and Martin Nduwimana of Kampala International University, contend that East Africa needs a platform mindset rather than a product mindset. A product mindset waits for a specific vaccine; a platform mindset prepares the system that can update, test, produce and deliver candidates as threats change. Ebola risk is species-specific, geographically uneven and socially fast-moving. A district can move from one suspicious death to hundreds of monitored contacts within days, and if the scientific system starts only after laboratory confirmation, it is already late. The 2025 Uganda response illustrated both the danger and the opportunity: WHO and partners worked with Ugandan investigators, regulators and international filovirus experts so that candidate vaccines and treatments could be accessed once Sudan virus disease was detected, and a clinical efficacy trial for a Sudan virus vaccine was launched during the emergency, a landmark moment for Sudan virus disease vaccine evaluation. That speed deserves celebration, the authors argue, but it should also make the region restless. If so much had to be assembled under pressure, the next task is to make readiness less heroic and more ordinary, aligning with the 100 Days Mission framework and the Coalition for Epidemic Preparedness Innovations’ platform technology approach, which emphasize moving from viral detection to vaccine deployment within shorter timeframes.
The scientific case for mRNA Ebola vaccines rests on the platform’s distinctive technical features. mRNA vaccines deliver genetic instructions that allow host cells to produce a target antigen, typically through lipid nanoparticle delivery. The platform enables rapid design after sequence availability, manufacturing processes that can be standardized across targets, and the option of testing updated constructs without rebuilding the entire production chain. For Ebola disease, the glycoprotein remains the obvious starting point because it mediates viral entry and has been the central antigen for several vaccine approaches. The evidence base is early but no longer empty. Meyer and colleagues reported that lipid nanoparticle-formulated modified mRNA vaccines based on Ebola virus glycoprotein induced Ebola-specific IgG and neutralizing antibody responses and protected guinea pigs after challenge. O’Donnell and colleagues extended the RNA platform logic to Sudan virus, showing single-dose replicon RNA protection in female guinea pigs. Stromberg and colleagues reported that an mRNA vaccine expressing Ebola virus glycoprotein induced high neutralizing antibody titers and protected mice against lethal challenge. These are not field efficacy data, and the authors are careful not to oversell them, but they justify serious platform development, especially for viral species where licensed vaccines remain unavailable.
Other vaccine platforms reinforce the same point from a different angle. Vesicular stomatitis virus-based Sudan virus vaccines have protected macaques in challenge studies, and a bivalent ChAdOx1 Ebola and Sudan virus vaccination has shown early clinical safety and immunogenicity in adults. The field is clearly moving beyond Zaire-only preparedness. mRNA candidates should therefore be judged alongside these approaches on durability, T cell responses, reactogenicity, tropical stability, dosing schedule, performance in previously exposed populations and feasibility during ring vaccination. Excitement, the authors warn, is useful only if it survives field reality.
A serious argument for mRNA Ebola preparedness cannot stop at biotechnology; the region needs an ecosystem. Genomic surveillance should identify the viral species and sequence relevant targets quickly. Regional laboratories should handle sequencing data, immunological assays and quality control. Regulators should maintain pre-reviewed emergency pathways that preserve rigour without wasting time. Trial sites need trained staff, community networks, adverse event monitoring and data systems before an outbreak begins. Parts of this architecture already exist. Uganda has strong research institutions and considerable outbreak experience. The WHO mRNA technology transfer hub in South Africa was established to strengthen mRNA vaccine production capacity on the continent and support African manufacturing self-determination beyond COVID-19, offering East Africa the prospect of developing capacity in antigen design, batch release and quality assurance through partnership rather than importing finished products. Africa CDC’s Partnerships for African Vaccine Manufacturing places vaccine production within a wider continental health security agenda, while the African Medicines Agency is positioned to accelerate preparedness by developing convergent regulatory standards and pre-approved trial protocols for investigational mRNA vaccines, reducing the time and cost of bringing candidates into outbreak response trials across fragmented national jurisdictions.
Community trust is part of the platform, not a soft add-on. Ebola vaccination is a social act carried out during fear: communities may be grieving, angry or suspicious, health workers exhausted, and rumors may move faster than contact tracing teams. The term mRNA may also bring back memories of COVID-19 disputes, political messaging and online misinformation. If mRNA Ebola preparedness is built only in laboratories, it may fail at the clinic gate, the village meeting or the burial negotiation. Survivors, religious leaders, local journalists, market leaders, ambulance teams, nurses, burial teams and community health workers should be part of the conversation from the start, understanding why a Sudan virus outbreak may require a different vaccine from a Zaire virus outbreak and why trial participation can be ethical during an emergency. Religious institutions deserve particular attention: during the 2014–2016 West Africa Ebola epidemic, faith leaders were pivotal in shaping community responses to safe burial practices, quarantine compliance and rumor messaging, and their networks can amplify misinformation with the same efficiency with which they transmit reassurance. Engaging faith leaders early, before outbreaks rather than during them, is therefore a structural requirement.
Manufacturing, cold chain and delivery pose equally blunt questions. mRNA readiness will mean little if the vaccine cannot leave the capital. Ebola outbreaks may occur in rural districts, conflict-affected zones, mining corridors, crowded urban settlements or border communities where electricity, roads and internet coverage are unreliable, and some mRNA products have demanding cold chain requirements, although formulation and stability work continues to improve. Delivery models should match outbreak epidemiology: ring vaccination remains attractive because it targets contacts and contacts of contacts around confirmed cases, while health worker vaccination may be needed early because nurses, laboratory staff, ambulance teams and cleaners can become both victims and amplifiers if infection prevention fails. Supply chain fragility presents a structural obstacle: African laboratories and health facilities have long depended on imported reagents, cold chain equipment and consumables, and disruptions caused by procurement bottlenecks, shipping delays, foreign exchange shortfalls or export restrictions can halt testing and undermine biosafety. The COVID-19 pandemic exposed this dependence acutely, with diagnostic reagents becoming scarce precisely when demand was highest. Manufacturing is also political: East Africa does not need every country to build a full mRNA plant, but it does need meaningful participation in antigen selection, batch release, quality systems, pharmacovigilance, trial leadership, fill-and-finish capacity where feasible and data ownership, otherwise mRNA preparedness risks becoming another form of dependence with better branding.
Perhaps the most formidable obstacle is the way science is funded on the African continent. Readiness is a continuous state of institutional memory, trained personnel, functional infrastructure and regularly rehearsed protocols, and that continuity is extremely difficult to sustain through the dominant model of competitive international grants won institution by institution and often year by year. When a grant cycle ends, trained laboratory scientists may leave for better-paid positions, data systems may go unmaintained and community engagement networks may go dormant. The recent and severe contraction of international research funding, including cuts to United States foreign assistance and the rollback of major global health funding streams, has affected African research institutions, clinical trial networks, surveillance systems and community health programs simultaneously. The epidemiological case for a different model is clear: every gap in surveillance and every hiatus in laboratory maintenance is a gap in which an outbreak can move from a single case to a regional emergency before detection. The cost of reactive response in 2014 was estimated in the tens of billions of dollars, while the cost of sustained preparedness is a fraction of that. The authors propose treating Ebola preparedness as a recurrent line item in national health budgets, pooling contributions through East African Community and African Union frameworks, and establishing a credible business case for mRNA manufacturing by diversifying platform applications toward improved malaria vaccines, tuberculosis boosters or maternal immunization strategies, providing continuous production and stabilized revenue streams that justify capital investment.
The deeper argument is readiness. East Africa has shown that emergency vaccine trials can be activated quickly when prior planning exists, and the region should now ask what it would take to make such speed normal. That requires investment in people as much as platforms: trial nurses, laboratory scientists, data managers, regulators, logisticians, community engagement teams and manufacturing specialists, along with political seriousness, because preparedness budgets are easy to cut when there is no outbreak on the evening news. There are risks: mRNA Ebola vaccines are not yet proven field tools, preclinical protection in guinea pigs or mice does not guarantee effectiveness in humans exposed during an outbreak, and reactogenicity, dosing schedules, durability and cold chain demands could limit use. There is also a fairness risk if the technology is developed mainly through external ownership, with African sites used only when outbreaks occur. Still, the opportunity is real. Ebola preparedness has often been framed as a race against time, and mRNA platforms can help with time, but only if the region prepares the track before the race begins. The next Ebola outbreak should not find East Africa beginning again; it should find a prepared ecosystem already capable of moving from viral sequence to local readiness with speed, fairness and scientific confidence, and the financial architecture to sustain that capability between outbreaks.
Subject of Research: Virology and infectious disease
Article Title: From outbreak response to regional readiness: reimagining mRNA vaccine platforms for Ebola preparedness in East Africa
Article References: Paul-Chima, U. O., & Nduwimana, M. (2026). From outbreak response to regional readiness: reimagining mRNA vaccine platforms for Ebola preparedness in East Africa. Frontiers in Tropical Diseases, 7, Article 1887687. https://doi.org/10.3389/fitd.2026.1887687
Image Credits: AI Generated
DOI: 10.3389/fitd.2026.1887687
Keywords: mRNA vaccines, Ebola, East Africa, Sudan virus, Bundibugyo virus, outbreak preparedness, genomic surveillance, vaccine manufacturing, Africa CDC, health policy, outbreak, response
News Source: Kristina Jarvis. (October 17, 2026). mRNA vaccine platforms could anchor Ebola preparedness in East Africa before the next outbreak. Scienmag.
